MML Investors Services’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-7,741
Closed -$203K 2214
2022
Q3
$203K Sell
7,741
-222
-3% -$5.87K ﹤0.01% 1936
2022
Q2
$202K Buy
7,963
+210
+3% +$5.14K ﹤0.01% 1911
2022
Q1
$245K Sell
7,753
-5,221
-40% -$175K ﹤0.01% 1842
2021
Q4
$525K Sell
12,974
-2,097
-14% -$81.3K ﹤0.01% 1385
2021
Q3
$526K Sell
15,071
-6,792
-31% -$211K ﹤0.01% 1318
2021
Q2
$600K Sell
21,863
-1,228
-5% -$35.1K 0.01% 1232
2021
Q1
$648K Buy
23,091
+2,416
+12% +$84.1K 0.01% 1133
2020
Q4
$537K Sell
20,675
-1,925
-9% -$46.6K 0.01% 1124
2020
Q3
$387K Buy
22,600
+6,447
+40% +$144K ﹤0.01% 1161
2020
Q2
$400K Sell
16,153
-19,862
-55% -$536K 0.01% 1099
2020
Q1
$500K Sell
36,015
-5,225
-13% -$65K 0.01% 866
2019
Q4
$417K Buy
41,240
+4,893
+13% +$41.1K 0.01% 1081
2019
Q3
$331K Sell
36,347
-8,599
-19% -$69.1K 0.01% 1137
2019
Q2
$357K Sell
44,946
-6,464
-13% -$64.7K 0.01% 1189
2019
Q1
$642K Buy
51,410
+1,712
+3% +$18.6K 0.01% 890
2018
Q4
$535K Sell
49,698
-1,962
-4% -$22.9K 0.01% 877
2018
Q3
$720K Buy
51,660
+34,920
+209% +$445K 0.01% 814
2018
Q2
$205K Buy
+16,740
New +$263K ﹤0.01% 1267

Other funds holding RCUS

MML Investors Services's RCUS Position: Q4 2022 in Review

MML Investors Services sold out of Arcus Biosciences (RCUS) in Q4 2022, closing a stake of 7,741 shares — an estimated $203K sold.

MML Investors Services first reported a position in RCUS in Q2 2018 and held it in 18 quarters. The position peaked at $720K in Q3 2018. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • MML Investors Services reported no remaining Arcus Biosciences position as of Q4 2022 after selling out during the quarter.
  • MML Investors Services sold 7,741 Arcus Biosciences shares in Q4 2022, an estimated $203K.
  • MML Investors Services first reported a position in Arcus Biosciences in Q2 2018 and held it in 18 quarters.
  • MML Investors Services's Arcus Biosciences position peaked at $720K in Q3 2018.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on MML Investors Services's 13F filing for Q4 2022, filed 13 Feb 2023.